Imatinib Sandoz Ltd (Imatinib Mesilate)

Imatinib mesylate blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By preventing these enzymes from phosphorylating downstream proteins, the drug stops proliferative signaling pathways, leading to reduced tumor cell division and increased apoptosis of the malignant cells.

The specific dose of Imatinib Sandoz Ltd is determined by the prescribing clinician based on the patient’s diagnosis, disease stage, weight, renal and hepatic function, and other individual factors. Healthcare professionals adjust the regimen to achieve optimal therapeutic response while minimizing adverse effects.

The safety of Imatinib Sandoz Ltd in pregnancy and lactation has not been established, and the product carries an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a qualified obstetrician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Imatinib Sandoz Ltd is a first‑generation tyrosine‑kinase inhibitor and is often used as a standard of care for BCR‑ABL‑positive leukemias and c‑KIT‑driven stromal tumors. Newer agents such as dasatinib or nilotinib may offer alternative potency or side‑effect profiles, but selection depends on disease characteristics, prior therapy, and individual patient tolerance.

Imatinib Sandoz Ltd should be stored at room temperature, below 25 °C, in its original packaging. The container should be kept tightly closed, protected from moisture and direct sunlight to maintain product stability throughout its shelf life.

The medication is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any dietary considerations to ensure consistent absorption.

Serious risks include severe neutropenia or thrombocytopenia, which can predispose to infections or bleeding; hepatotoxicity with elevated liver enzymes; cardiac failure or reduced left‑ventricular function; and rare but severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical evaluation is required if any of these occur.

Patients with known hypersensitivity to imatinib mesylate or any of the tablet’s excipients should avoid the product. Additionally, individuals with uncontrolled cardiac disease, severe hepatic impairment, or those currently receiving strong CYP3A4 inhibitors without dose adjustment should not use it without close medical supervision.